Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Aripiprazole. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 20/20 | 1.00 |
| ▸ | HTR1A known ✓ | P08908 | 3/20 | 1.00 |
| ▸ | HTR2A known ✓ | P28223 | 3/20 | 1.00 |
| ▸ | DRD3 | P35462 | 5/20 | 1.00 |
| ▸ | DRD4 | P21917 | 4/20 | 1.00 |
| ▸ | HTR2B | P41595 | 3/20 | 1.00 |
| ▸ | DRD1 | P21728 | 2/20 | 1.00 |
| ▸ | DRD5 | P21918 | 2/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | HTR6 | P50406 | 2/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | HTR3B | O95264 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | PGR | P06401 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Aripiprazole SCHEMBL29356997 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475637 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29475638 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL982189 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL29438823 | 1.00 | DRD2 (1.00) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL7097505 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL236666 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL5147095 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL30958766 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A | |
| Aripiprazole SCHEMBL31174198 | 0.99 | DRD2 (0.98) | DRD2DRD3DRD4HTR1AHTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 30065 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260146048-A1 | NOVEL BISINDOLYLMALEIMIDE KINASE INHIBITORS | 4M THERAPEUTICS INC. (US) | 2026-05-28 | — | — | US | claimed |
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| CN-110204488-B | Preparation method of lunar Gui Xiana risperidone | SICHUAN KELUN PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122094963-A | Cardioprotective lipids and methods of use | — | 2026-05-26 | — | — | CN | claimed |
| CN-116199626-B | Method for removing aripiprazole BQB impurities | ZHEJIANG HUAHAI PHARMACEUTICAL CO.,LTD. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122079853-A | N-substituted indoles and other heterocyclic compounds for the treatment of brain diseases | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026102521-A1 | USE OF A PURINE COMPOUND FOR THE TREATMENT OF AUTISM SPECTRUM DISORDER, RETT SYNDROME, AND FRAGILE X SYNDROME | MARVEL BIOTECHNOLOGY (CA) | 2026-05-21 | — | — | WO | claimed |
| US-12629366-B2 | Pharmaceutical compositions comprising sorbitan esters | ALKERMES PHARMA IRELAND LIMITED (IE) | 2026-05-19 | — | — | US | claimed |
| EP-4740962-A1 | PHARMACEUTICAL COMPOSITION, FORMULATION CONTAINING PHARMACEUTICAL COMPOSITION, KIT CONTAINING PHARMACEUTICAL COMPOSITION, PREPARATION METHOD FOR PHARMACEUTICAL COMPOSITION, AND USE OF PHARMACEUTICAL COMPOSITION | Shanghai WD Pharmaceutical Co., Ltd (CN) | 2026-05-13 | — | — | EP | claimed |
| US-12624036-B2 | Method of treating post-traumatic stress disorder | INTRA-CELLULAR THERAPIES, INC. (US) | 2026-05-12 | — | — | US | claimed |
| US-20020076437-A1 | Flashmelt oral dosage formulation | BRISTOL-MYERS SQUIBB COMPANY | 2002-06-20 | — | — | US | claimed |
| WO-2002033112-A2 | PROTEIN-PROTEIN INTERACTIONS IN NEURODEGENERATIVE DISEASES | MYRIAD GENETICS, INC. (US) | 2002-04-25 | — | — | WO | claimed |
| EP-1145711-A1 | Flash-melt oral dosage formulation | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-10-17 | — | — | EP | claimed |
| CN-1317309-A | Instant oral medincinal preparation | BRISTOL MYERS SQUIBB CO (US) | 2001-10-17 | — | — | CN | claimed |
| EP-0782692-A1 | SENSOR ARRANGEMENT AND METHOD OF DETECTING MEASURED VALUES USING SAID SENSOR ARRANGEMENT | Micro-Epsilon Messtechnik GmbH & Co. KG (DE) | 1997-07-09 | — | — | EP | claimed |
| WO-1996009516-A1 | SENSOR ARRANGEMENT AND METHOD OF DETECTING MEASURED VALUES USING SAID SENSOR ARRANGEMENT | MICRO-EPSILON MESSTECHNIK GMBH & CO. KG (DE) | 1996-03-28 | — | — | WO | claimed |
| EP-0367141-B1 | Carbostyril derivatives | OTSUKA PHARMA CO LTD (JP) | 1996-01-10 | — | — | EP | claimed |
| US-5006528-A | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-04-09 | — | — | US | claimed |
| EP-0367141-A2 | Carbostyril derivatives | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1990-05-09 | — | — | EP | claimed |
| EP-0228345-A1 | Magnetic-release mechanism for an earth fault circuit breaker | CMC Carl Maier + Cie AG (CH) | 1987-07-08 | — | — | EP | claimed |